Regarding conservative treatment, 84.1% of patients did not receive anti-osteoporosis medication, 21 patients (9.3%) used bisphosphonates, 3 (1.3%) used teriparatide, 0 (0%) used romosozumab, 3 (1.3%) used denosumab, and 9 (4%) used selective estrogen receptor modulators at baseline. The gene discussed is ESR1; the disease is osteoporosis.